Our Experiences with Erlotinib in Second and Third Line Treatment Patients with Advanced Stage Iiib/ Iv Non-Small Cell Lung Cancer. Biomol Biomed. 2008;8(4):386-390. doi:10.17305/bjbms.2008.2905